Critical Contrast: Onconetix (NASDAQ:ONCO) vs. HAVN Life Sciences (OTCMKTS:HAVLF)

HAVN Life Sciences (OTCMKTS:HAVLF) and Onconetix (NASDAQ:ONCO) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Analyst Ratings

This is a summary of current ratings for HAVN Life Sciences and Onconetix, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HAVN Life Sciences	0	0	0	0	0.00
Onconetix	1	0	0	0	1.00

Given HAVN Life Sciences’ higher possible upside, analysts clearly believe HAVN Life Sciences is more favorable than Onconetix.

Institutional and Insider Ownership

23.9% of Onconetix shares are owned by institutional investors. 0.3% of Onconetix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares HAVN Life Sciences and Onconetix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
HAVN Life Sciences	N/A	N/A	N/A
Onconetix	-1,575.89%	-91.95%	-53.76%

Valuation & Earnings

This table compares HAVN Life Sciences and Onconetix”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HAVN Life Sciences	N/A	N/A	N/A	N/A	N/A
Onconetix	$810,000.00	3.17	-$14.03 million	$248.12	0.00

HAVN Life Sciences has higher earnings, but lower revenue than Onconetix.

About HAVN Life Sciences

HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is headquartered in Richmond, Canada.

About Onconetix

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.